Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Duintjer Tebbens, Radboud J ^a   Hampton, Lee M ^b   Thompson, Kimberly M ^a  

^a Kid Risk Inc   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Dynamic modeling; Eradication; Oral poliovirus vaccine; Polio; Risk management; Vaccine derived poliovirus

Indexed keywords

ORAL POLIOMYELITIS VACCINE; SEROTYPE 2 ORAL POLIOVIRUS VACCINE; UNCLASSIFIED DRUG; POLIOMYELITIS VACCINE;

ARTICLE; DRUG WITHDRAWAL; EPIDEMIC; IMMUNIZATION; INFECTION PREVENTION; POLIOMYELITIS; RISK FACTOR; RISK MANAGEMENT; VIRUS TRANSMISSION; DISEASE OUTBREAKS; GLOBAL HEALTH; HUMAN; IMMUNOLOGY; POLIOMYELITIS VIRUS; SEROTYPE; THEORETICAL MODEL;

DISEASE OUTBREAKS; GLOBAL HEALTH; HUMANS; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RISK MANAGEMENT; SEROGROUP;

EID: 84969931989     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1536-9     Document Type: Article

References (34)

1. World Health Organization. Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013-2018). Geneva: Report number: WHO/POLIO/13.02; 2013.
2. Global Polio Eradication Initiative; World ready for OPV2 cessation [ http://www.polioeradication.org/mediaroom/newsstories/World-ready-for-OPV2-cessation-/tabid/526/news/1181/Default.aspx?popUp=true , Accessed 28 Jan 2015]
3. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S475-84.
4. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15:389.
5. Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: Oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.
6. Global Polio Eradication Initiative; Operational Framework for Monovalent Oral Poliovirus Type 2 (mOPV2) deployment and replenishment (during the endgame period) [ http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/mOPV2_Operational_Framework.pdf , Accessed 25 Sept 2015]
7. Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.
8. Immunization Systems Management Group of the Global Polio Eradication Initiative. Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine - worldwide, 2013-2016. MMWR Morb Mortal Wkly Rep. 2015;64(25):669-702.
9. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. BMC Infect Dis. 2015;15(66):1.
10. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S485-97.
11. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599.
12. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544-605.
13. Anis E, Kopel E, Singer S, Kaliner E, Moerman L, Moran-Gilad J, Sofer D, Manor Y, Shulman L, Mendelson E et al.: Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013, 18(38).
14. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800-12.
15. Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses. Vaccine. 2015;33(3):1568-77.
16. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703-49.
17. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014;14:45.
18. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606-46.
19. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, et al. Review: Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Anal. 2013;23(4):680-702.
20. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.
21. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647-63.
22. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210 Suppl 1:S412-23.
23. World Bank; World Bank list of economies (October 2013) [ http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS , Accessed 23 Dec 2013]
24. Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.
25. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210 Suppl 1:S398-411.
26. World Health Organization; Global Polio Eradication Initiative -- circulating vaccine-derived poliovirus cases 2000-2015 [ http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx , Accessed 5 Aug 2015]
27. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape J Med. 2008;10(8):190.
28. Barrett S. Polio eradication: Strengthening the weakest links. Health Affairs. 2009;28(4):1079-90.
29. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA. 1996;275(21):1639-45.
30. Más Lago P, Bravo JR, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, et al. Lesson from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ. 1994;72(2):221-5.
31. World Health Organization Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Bull World Health Organ. 1996;74(3):253-68.
32. World Health Organization. Polio Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) use after Global Polio Eradication, Framework for National Policy Makers in OPV-using Countries. Geneva: Report number: WHO/POL/05.02; 2005.
33. Duintjer Tebbens RJ, Hampton LM, Thompson KM: Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use. 2016;16. doi: 10.1186/s12879-016-1537-8. (In press)
34. El-Sayed N, El-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359(16):1655-65.